Show simple item record

dc.contributor.authorIJzerman, MJ
dc.contributor.authorde Boer, J
dc.contributor.authorAzad, A
dc.contributor.authorDegeling, K
dc.contributor.authorGeoghegan, J
dc.contributor.authorHewitt, C
dc.contributor.authorHollande, F
dc.contributor.authorLee, B
dc.contributor.authorTo, YH
dc.contributor.authorTothill, RW
dc.contributor.authorWright, G
dc.contributor.authorTie, J
dc.contributor.authorDawson, S-J
dc.date.accessioned2021-02-04T10:57:59Z
dc.date.available2021-02-04T10:57:59Z
dc.date.issued2021-01-01
dc.identifierpii: diagnostics11010103
dc.identifier.citationIJzerman, M. J., de Boer, J., Azad, A., Degeling, K., Geoghegan, J., Hewitt, C., Hollande, F., Lee, B., To, Y. H., Tothill, R. W., Wright, G., Tie, J. & Dawson, S. -J. (2021). Towards Routine Implementation of Liquid Biopsies in Cancer Management: It Is Always Too Early, until Suddenly It Is Too Late. DIAGNOSTICS, 11 (1), https://doi.org/10.3390/diagnostics11010103.
dc.identifier.issn2075-4418
dc.identifier.urihttp://hdl.handle.net/11343/259968
dc.description.abstractBlood-based liquid biopsies are considered a new and promising diagnostic and monitoring tool for cancer. As liquid biopsies only require a blood draw, they are non-invasive, potentially more rapid and assumed to be a less costly alternative to genomic analysis of tissue biopsies. A multi-disciplinary workshop (n = 98 registrations) was organized to discuss routine implementation of liquid biopsies in cancer management. Real-time polls were used to engage with experts' about the current evidence of clinical utility and the barriers to implementation of liquid biopsies. Clinical, laboratory and health economics presentations were given to illustrate the opportunities and current levels of evidence, followed by three moderated break-out sessions to discuss applications. The workshop concluded that tumor-informed assays using next-generation sequencing (NGS) or PCR-based genotyping assays will most likely provide better clinical utility than tumor-agnostic assays, yet at a higher cost. For routine application, it will be essential to determine clinical utility, to define the minimum quality standards and performance of testing platforms and to ensure their use is integrated into current clinical workflows including how they complement tissue biopsies and imaging. Early health economic models may help identifying the most viable application of liquid biopsies. Alternative funding models for the translation of complex molecular diagnostics, such as liquid biopsies, may also be explored if clinical utility has been demonstrated and when their use is recommended in multi-disciplinary consensus guidelines.
dc.languageEnglish
dc.publisherMDPI
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.titleTowards Routine Implementation of Liquid Biopsies in Cancer Management: It Is Always Too Early, until Suddenly It Is Too Late
dc.typeJournal Article
dc.identifier.doi10.3390/diagnostics11010103
melbourne.affiliation.departmentMelbourne School of Population and Global Health
melbourne.affiliation.departmentClinical Pathology
melbourne.affiliation.departmentSir Peter MacCallum Department of Oncology
melbourne.affiliation.departmentMedical Biology (W.E.H.I.)
melbourne.source.titleDiagnostics
melbourne.source.volume11
melbourne.source.issue1
melbourne.source.pages103-103
dc.rights.licenseCC BY
melbourne.elementsid1488564
melbourne.openaccess.pmchttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC7826562
melbourne.contributor.authorDegeling, Koen
melbourne.contributor.authorTothill, Richard
melbourne.contributor.authorDawson, Sarah-Jane
melbourne.contributor.authorTie, Jeanne
melbourne.contributor.authorLee, Belinda
melbourne.contributor.authorIJzerman, Maarten
melbourne.contributor.authorHollande, Frederic
melbourne.contributor.authorAzad, Arun
dc.identifier.eissn2075-4418
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record